Small-Cap Stock Watch: Key Catalysts This Week (January 26–30)

From corporate updates to investor events, we’ve tracked the full scope of small-cap catalysts slated for the week ahead. Here’s your preview for January 26–30.

--

DealFlow Discovery Conference 2026

One of the premier events for growth companies and investors, DealFlow is a high-impact platform featuring CEO-led presentations from 125+ companies. Attendees include institutional investors, equity analysts, brokers, fund managers, and market movers — over 1,250 participants expected.

Keynote Speaker Alan Patricof — Chairperson & Co-Founder of Primetime Partners, and author of No Red Lights: Reflections on Life, 50 Years in Venture Capital, and Never Driving Alone

Participating Companies: TIVC, MYSZ, AREB, HCTI, MEHA, ASNS, XHLD, BKYI, PHIO, CJMB, SNGX, KAPA, SOPA, NNVC, FBLG, LIXT, JUNS, WGRX, SJ, LITM, INDO, NOMA, OPTT, HOVR, PROP, WWR, ZENA, PERF, TYGO, TRX, DVLT, FUFU

Other Companies with Material Events This Week

Healthcare & Biotech

CDIO → Will host an in-person heart health education event on January 26 at 11:30 a.m. CT at the Southdale YMCA. Led by Dr. Robert Philibert, MD, Ph.D., the session will cover cardiovascular risk reduction, personalized health insights, and modern heart health tools. Team members will be on-site to support community engagement.

SLXN → Management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit (Jan 27–29, Boston). They’ll discuss SIL204, a next-gen siRNA therapy targeting KRAS mutations, expected to enter Phase 2/3 trials for pancreatic cancer in mid-2026. One-on-one investor meetings will also be hosted.

PFSA → Will present findings from its tissue oxygen monitoring pilot study at LINC 2026 on January 28 at 9:45 a.m. CET, Hall 2, Trade Fair Leipzig. The event takes place from January 27–30.

SKYE → Will present at Keystone’s Obesity Therapeutics Conference on January 28 at 7:30 p.m. Key data highlights nimacimab alone, in combination with tirzepatide, and as maintenance therapy. The presentation will explore mechanisms of weight loss durability and treatment optimization.

ANVS → Will host a corporate update webinar and live Q&A on January 28 at 4:30 p.m. ET, led by CEO Maria Maccecchini, Ph.D., covering progress, clinical programs, and 2026 strategy.

AGEN → Will host its Access to Acceleration stakeholder webcast on January 28 at 4:00 p.m. ET, discussing clinical momentum and global expansion of the BOT+BAL program, with commentary from leadership and an international oncology expert.

AQST → Continues engagement with the FDA regarding its NDA for Anaphylm™ ahead of the January 31 PDUFA date. The program includes 11 clinical studies and demonstrates PK performance comparable to leading epinephrine auto-injectors with favorable safety data.

Tech & Innovation

TNMG → Confirmed keynote and session speakers for TechGALA Japan 2026, to be held January 27–29 in Nagoya City. Its subsidiary is leading the event as the primary communications partner.

OSRH → Expected to complete its share exchange with Woori IO on January 26, aligning with a phased digital health commercialization strategy. The move supports accelerated market entry and reflects updated FDA guidance.

AIMD → Will join a fireside chat hosted by Water Tower Research on January 26 at 11:00 a.m. ET, discussing its SmellTech platform, commercial deployment, and strategic roadmap with Trusval Technology.

LUCY → Will participate in The Vision Council Executive Summit 2026, held January 26–28 in Amelia Island, FL. The event convenes industry leaders to explore emerging trends and technology shaping the future of vision care.

HCTI → Announced a definitive agreement to acquire Teyame AI and related Spanish CX assets. The $50 million deal is expected to close January 29, structured via cash, stock, and contingent equity.

AUUD → Continues progress on its merger into McCarthy Finney (MCFN), with a binding agreement expected by end of January. The new holding company will focus on AI and Web3 technology platforms.

Maritime & Energy

PXS → Will present at Capital Link’s Online Maritime Series on January 28 at 10:00 a.m. ET, with strategy updates from the chairman and CFO.

DSX → Scheduled to present on January 29 at 11:00 a.m. ET as part of the same Capital Link series. The session will include insights from multiple senior executives across corporate development, governance, and technical operations.

AREC → Will attend the Battery Innovation Forum on January 30 in Miami, FL, an invite-only summit sponsored by Dow and co-located with the Formula E Race. The forum will spotlight innovation across the battery supply chain.

Capital Markets & Corporate Milestones

AVX → Will appear at the Digital Asset Virtual Investor Conference on January 27, highlighting ongoing developments in digital asset and blockchain initiatives.

KGEI → Executives will participate in Renmark’s Virtual Non-Deal Roadshow on January 28 at 9:00 a.m. PT, offering updates to institutional investors.

LXRX → Will ring the Nasdaq Closing Bell on January 27 in honor of its 30th anniversary, celebrating a legacy in cardiometabolic and neuropathic pain therapeutics.

BCAB → Entered into an SPV transaction to fund Phase 3 development of Oz-V, with an initial $5M closing expected January 30. The structure includes a 65/35 ownership split with Inversagen AI and will support a 2L+ OPSCC registrational study launch in Q1.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.